Cabot vs Chemours
CBT and CC side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBT and CC compare
Cabot is the larger company, worth 1.8 times as much as Chemours ($3.7B against $2.1B).
Cabot grew revenue faster over the last twelve months (16.6% versus 0.07% for Chemours).
Cabot keeps more of each dollar of sales as profit, with a net margin of 6.4% compared with −2.6% at Chemours.
Both pay dividends: Cabot yields 2.6% and Chemours 2.6%.
Cabot scores higher on the StockData Score (19 against 5 for Chemours), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBT | CC |
|---|---|---|
| Size and price | ||
| Market cap | $3.7B | $2.1B |
| Share price | $72.23 | $13.72 |
| Change, 1 year | 18.2% | 7.6% |
| Change, 5 years | 21.9% | −56.8% |
| Beta (5Y) | 0.94 | 1.57 |
| Employees | 4,100 | 5,700 |
| StockData Score | ||
| Total score | 19 (better) | 5 |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 13.3× | – |
| P/S | 0.8× | 0.4× (better) |
| P/B | 2.3× (better) | 13.3× |
| EV/EBITDA | 5.6× (better) | 7.2× |
| P/FCF | 8.0× (better) | 9.8× |
| PEG | 0.72 | – |
| FCF yield | 12.6% (better) | 10.2% |
| Fair value | $137.19 | – |
| Margin of safety | 47.4% | – |
| Growth | ||
| Revenue growth (TTM) | 16.6% (better) | 0.07% |
| Revenue growth, 5Y average | 7.3% (better) | 3.2% |
| Net income growth (TTM) | −32.8% | – |
| EPS growth (TTM) | −29.8% | – |
| Profitability | ||
| Gross margin | 23.5% (better) | 15.2% |
| Operating margin | 14.5% | – |
| Net margin | 6.4% (better) | −2.6% |
| FCF margin | 10.3% (better) | 3.6% |
| Return on equity | 19.2% (better) | −71.8% |
| Return on invested capital | 15.1% | – |
| Financial health | ||
| Debt / equity | 0.79 (better) | 24.73 |
| Net debt / EBITDA | 1.16 (better) | 4.32 |
| Interest coverage | 7.1× | – |
| Current ratio | 1.47 | 1.81 (better) |
| Altman Z-score | 3.49 (better) | 1.42 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.6% | 2.6% (better) |
| Payout ratio | 41.6% | – |
| Years of dividend growth | 4 (better) | 0 |
| Dividend growth, 5Y average | 4.7% (better) | −12.5% |
| Buyback yield | 4.8% | – |
| Shareholder yield | 7.4% (better) | 2.6% |
| Ownership | ||
| Held by institutions | 104% | 90.2% |
| Held by insiders | 2.1% | 0.96% |
| Insider net buying, 12 months | −$19.6M | $489K (better) |
| Short interest, % of float | 10.3% | 9.8% |
Go deeper
- CBT stock overview
- CBT income statement
- CBT valuation and score
- CC stock overview
- CC income statement
- CC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.